vs
ANI PHARMACEUTICALS INC（ANIP）与Axos Financial, Inc.（AX）财务数据对比。点击上方公司名可切换其他公司
Axos Financial, Inc.的季度营收约是ANI PHARMACEUTICALS INC的1.6倍（$392.2M vs $247.1M），Axos Financial, Inc.净利率更高（31.8% vs 11.1%，领先20.7%），过去两年ANI PHARMACEUTICALS INC的营收复合增速更高（34.1% vs 16.1%）
ANI制药是一家总部位于美国的特种制药企业，专注于研发、生产和销售仿制药及品牌处方药，核心产品覆盖皮肤科、肿瘤、中枢神经系统治疗、抗感染等领域，主要服务美国境内的医疗机构、零售药房和患者群体。
Axos Financial是总部位于美国内华达州拉斯维加斯的银行控股公司，旗下拥有直销银行Axos Bank，同时提供注册投资顾问服务及电子交易平台，深耕数字化金融赛道，可为用户提供多元便捷的金融服务解决方案。
ANIP vs AX — 直观对比
营收规模更大
AX
是对方的1.6倍
$247.1M
净利率更高
AX
高出20.7%
11.1%
两年增速更快
ANIP
近两年复合增速
16.1%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $247.1M | $392.2M |
| 净利润 | $27.5M | $124.7M |
| 毛利率 | — | — |
| 营业利润率 | 14.1% | — |
| 净利率 | 11.1% | 31.8% |
| 营收同比 | 29.6% | — |
| 净利润同比 | 367.5% | 18.5% |
| 每股收益（稀释后） | $1.14 | $2.15 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ANIPAX
| Q1 26 | — | $392.2M | ||
| Q4 25 | $247.1M | $385.1M | ||
| Q3 25 | $227.8M | $323.4M | ||
| Q2 25 | $211.4M | $321.4M | ||
| Q1 25 | $197.1M | $308.8M | ||
| Q4 24 | $190.6M | $307.9M | ||
| Q3 24 | $148.3M | $320.7M | ||
| Q2 24 | $138.0M | $290.9M |
净利润ANIPAX
| Q1 26 | — | $124.7M | ||
| Q4 25 | $27.5M | $128.4M | ||
| Q3 25 | $26.6M | $112.4M | ||
| Q2 25 | $8.5M | $110.7M | ||
| Q1 25 | $15.7M | $105.2M | ||
| Q4 24 | $-10.3M | $104.7M | ||
| Q3 24 | $-24.2M | $112.3M | ||
| Q2 24 | $-2.3M | $104.9M |
营业利润率ANIPAX
| Q1 26 | — | — | ||
| Q4 25 | 14.1% | 45.6% | ||
| Q3 25 | 15.9% | 46.3% | ||
| Q2 25 | 6.6% | 48.5% | ||
| Q1 25 | 13.3% | 47.9% | ||
| Q4 24 | -2.3% | 48.8% | ||
| Q3 24 | -13.8% | 49.6% | ||
| Q2 24 | 3.7% | 49.6% |
净利率ANIPAX
| Q1 26 | — | 31.8% | ||
| Q4 25 | 11.1% | 33.3% | ||
| Q3 25 | 11.7% | 34.7% | ||
| Q2 25 | 4.0% | 34.4% | ||
| Q1 25 | 8.0% | 34.1% | ||
| Q4 24 | -5.4% | 34.0% | ||
| Q3 24 | -16.3% | 35.0% | ||
| Q2 24 | -1.7% | 36.0% |
每股收益（稀释后）ANIPAX
| Q1 26 | — | $2.15 | ||
| Q4 25 | $1.14 | $2.22 | ||
| Q3 25 | $1.13 | $1.94 | ||
| Q2 25 | $0.36 | $1.89 | ||
| Q1 25 | $0.69 | $1.81 | ||
| Q4 24 | $-0.45 | $1.80 | ||
| Q3 24 | $-1.27 | $1.93 | ||
| Q2 24 | $-0.14 | $1.75 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $285.6M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $540.7M | $3.1B |
| 总资产 | $1.4B | $29.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ANIPAX
| Q1 26 | — | — | ||
| Q4 25 | $285.6M | $1.0B | ||
| Q3 25 | $262.6M | $2.6B | ||
| Q2 25 | $217.8M | $1.9B | ||
| Q1 25 | $149.8M | $2.0B | ||
| Q4 24 | $144.9M | $2.4B | ||
| Q3 24 | $145.0M | $2.6B | ||
| Q2 24 | $240.1M | $2.0B |
总债务ANIPAX
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $312.7M | ||
| Q1 25 | — | $377.4M | ||
| Q4 24 | — | $358.7M | ||
| Q3 24 | — | $313.5M | ||
| Q2 24 | — | $325.7M |
股东权益ANIPAX
| Q1 26 | — | $3.1B | ||
| Q4 25 | $540.7M | $2.9B | ||
| Q3 25 | $505.8M | $2.8B | ||
| Q2 25 | $436.8M | $2.7B | ||
| Q1 25 | $418.6M | $2.6B | ||
| Q4 24 | $403.7M | $2.5B | ||
| Q3 24 | $405.9M | $2.4B | ||
| Q2 24 | $455.8M | $2.3B |
总资产ANIPAX
| Q1 26 | — | $29.2B | ||
| Q4 25 | $1.4B | $28.2B | ||
| Q3 25 | $1.4B | $27.4B | ||
| Q2 25 | $1.3B | $24.8B | ||
| Q1 25 | $1.3B | $24.0B | ||
| Q4 24 | $1.3B | $23.7B | ||
| Q3 24 | $1.3B | $23.6B | ||
| Q2 24 | $920.8M | $22.9B |
负债/权益比ANIPAX
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.12× | ||
| Q1 25 | — | 0.14× | ||
| Q4 24 | — | 0.14× | ||
| Q3 24 | — | 0.13× | ||
| Q2 24 | — | 0.14× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $30.4M | — |
| 自由现金流经营现金流 - 资本支出 | $29.1M | — |
| 自由现金流率自由现金流/营收 | 11.8% | — |
| 资本支出强度资本支出/营收 | 0.5% | — |
| 现金转化率经营现金流/净利润 | 1.10× | — |
| 过去12个月自由现金流最近4个季度 | $171.4M | — |
8季度趋势，按日历期对齐
经营现金流ANIPAX
| Q1 26 | — | — | ||
| Q4 25 | $30.4M | $104.1M | ||
| Q3 25 | $44.1M | $118.4M | ||
| Q2 25 | $75.8M | $490.3M | ||
| Q1 25 | $35.0M | $73.7M | ||
| Q4 24 | $15.9M | $162.5M | ||
| Q3 24 | $12.5M | $70.8M | ||
| Q2 24 | $17.4M | $305.5M |
自由现金流ANIPAX
| Q1 26 | — | — | ||
| Q4 25 | $29.1M | $85.4M | ||
| Q3 25 | $38.0M | $109.3M | ||
| Q2 25 | $71.8M | $436.1M | ||
| Q1 25 | $32.5M | $65.1M | ||
| Q4 24 | $13.5M | $156.4M | ||
| Q3 24 | $7.7M | $53.0M | ||
| Q2 24 | $13.0M | $269.5M |
自由现金流率ANIPAX
| Q1 26 | — | — | ||
| Q4 25 | 11.8% | 22.2% | ||
| Q3 25 | 16.7% | 33.8% | ||
| Q2 25 | 34.0% | 135.7% | ||
| Q1 25 | 16.5% | 21.1% | ||
| Q4 24 | 7.1% | 50.8% | ||
| Q3 24 | 5.2% | 16.5% | ||
| Q2 24 | 9.4% | 92.6% |
资本支出强度ANIPAX
| Q1 26 | — | — | ||
| Q4 25 | 0.5% | 4.9% | ||
| Q3 25 | 2.7% | 2.8% | ||
| Q2 25 | 1.9% | 16.9% | ||
| Q1 25 | 1.3% | 2.8% | ||
| Q4 24 | 1.3% | 2.0% | ||
| Q3 24 | 3.2% | 5.5% | ||
| Q2 24 | 3.2% | 12.4% |
现金转化率ANIPAX
| Q1 26 | — | — | ||
| Q4 25 | 1.10× | 0.81× | ||
| Q3 25 | 1.66× | 1.05× | ||
| Q2 25 | 8.87× | 4.43× | ||
| Q1 25 | 2.23× | 0.70× | ||
| Q4 24 | — | 1.55× | ||
| Q3 24 | — | 0.63× | ||
| Q2 24 | — | 2.91× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
AX
| Net Interest Income | $306.3M | 78% |
| Noninterest Income | $86.0M | 22% |
